Shiga toxins I and II produced by Escherichia coli O157: H7 lead to hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS) in humans. 11, 12, 14 Consumption of undercooked contaminated beef is often the source of human E. coli infection. In the United States between 1982 and 1994, ground beef was responsible for 22 outbreaks of human disease. 4 Cattle shedding E. coli O157:H7 in their feces do so intermittently and show no clinical signs of disease. 5, [7] [8] [9] There is growing need for collecting samples from livestock before slaughter for determining E. coli O157:H7 prevalence and, as part of livestock producer programs such as Hazard analysis critical control point (HACCP), so that efforts can be made to reduce pathogens before the animals are transported to slaughter. Tests are needed to screen large numbers of samples quickly for food-borne pathogens. A commercially available enzyme immunoassay (EIA) a for detection of Shiga toxins I and II produced by enterohemorrhagic E. coli (EHEC) in diarrheal stool samples and clinical isolates from humans was evaluated as a presumptive test for E. coli O157:H7 in nondiarrheal bovine feces. Escherichia coli O157:H7 can produce either or both Shiga toxins in varying quantities. This EIA targets preformed Shiga toxin but does not identify bacterial species or serotypes. Bacteria in the sample must have produced Shiga toxin when a positive results occurs because the EIA does not detect Shiga toxin genes.
Although E. coli O157:H7 is the most frequent (80%) Shiga toxin-producing organism isolated from HC and HUS patients, 6 at least 100 other EHEC serotypes have been associated with these conditions. 3 The prevalence of this organism is low in environmental, live animal, and carcass samples, so many samples must be collected and tested to determine its presence. Thus, the Shiga toxin EIA might be used to narrow the search for a particular Shiga toxin-producing organism. Although the material costs of the Shiga toxin EIA are higher than the material costs for bacterial culture, the labor costs of bacterial culture are considerably higher than the cost of the EIA. The results from the Shiga toxin EIA are available within 1 day instead of 4 days.
Test sensitivity and specificity may differ for samples that originate from nonclinical or clinical cases than from experimentally spike samples that are used to develop the test. Therefore, field samples rather than spiked samples were used to evaluate the Shiga toxin EIA. The purpose of this research was to determine if the Shiga toxin EIA could be used to identify E. coli O157:H7-positive samples of nondiarrheal bovine feces. If the Shiga toxin EIA is both sen- sitive and specific for E. coli O157:H7 in fecal samples from clinically normal animals, then the test could be incorporated into an on-going livestock pathogen reduction program.
Individual fresh fecal pat samples (2,297) were collected monthly during 1997 from 10 Kansas cow-calf ranches. On each visit to a ranch, 10% of the cattle were sampled. 15 Samples were transported and kept on ice until processed, within 4-8 hours after collection. Samples were analyzed the same day using the Shiga toxin EIA and E. coli O157:H7 selective bacterial culture methods.
Samples were cultured following standard published methods. 10 Ten grams of feces was added to 90 ml of trypticase soy broth b modified with 4 g/ml of vancomycin, c 50 g/ml cefixime, c 200 g/ml of novobicin, c and 5 g/ml of cefsulodin c (MTsb) in a filter stomacher bag and stomached d for 30 seconds. The bags were incubated for 12 hours at 37 C. After incubation, 2 1-ml aliquots were put into 2 sterile centrifuge tubes. The contents of 1 tube were used for immunomagnetic separation and the contents of the other tube were used for the Shiga toxin EIA. Immunomagnetic separation was done according to the manufacturer's e instructions. Twenty microliters of immunoglobulin-bound magnetic beads e was added to 1 of the broth tubes and incubated at room temperature on a rotating platform e for 30 minutes. After incubation, the beads were magnetically e captured and rinsed 3 times. After the last wash, the beads were resuspended in 100 1 of wash buffer, added to 9 ml of MTsb, and incubated for 18 hours at 37 C. After incubation, a swab sample was plated onto CT-SMAC b,e and incubated for an additional 18 hours. After incubation, suspect colonies (colorless) were picked and subcultured onto blood agar plates f and incubated for 18 hours at 37 C. After incubation, colonies were confirmed to be E. coli O157:H7 by latex agglutination f and biochemical testing. g Isolates that were identified as E. coli O157:H7 were stored on Protect beads h at Ϫ80 C.
All supplies for the immunoassay were provided in the manufacturer's kit and were used to perform the assay according to the manufacturer's a instructions. After incubation, broth from the stomacher bag was diluted and added to microwells that contained bound monoclonal antibodies. The positive and negative controls were added to the proper positions in the microwell plate. The plate was incubated for 1 hour at room temperature and washed. The polyclonal detection antibody then was allowed to bind for 30 minutes at room temperature. The plate was washed again, and enzyme conjugate was added, followed by incubation for 30 minutes at room temperature and another wash. Substrate solution was added and incubated for 10 minutes at room temperature before stop solution was added. The plate was examined at 450 nm. A yellow color indicated a positive reaction.
The kappa statistic was used as a measure of agreement between culture and the Shiga toxin EIA. A kappa of Ͻ0.4 indicates poor agreement, 0.4-0.7 indicates fair agreement, and Ͼ0.7 indicates good agreement. 16 Prevalence of E. coli O157:H7 in 10 Kansas cow-calf ranches, as determined by selective bacterial culture, was 1.6% (36/2,297). However, prevalence of non-E. coli O157: H7 Shiga toxin-producing bacteria was higher (5.8%), as determined by Shiga toxin EIA. Of the 136 samples that were positive for Shiga toxin, only 2 were positive for E. coli O157:H7 by culture ( Table 1) .
The sensitivity of the Shiga toxin EIA for detection of toxin-positive E. coli O157:H7 was 5.5% (2/36), and the specificity was 94.1% (2,127/2,261) . The probability that the sample did not contain E. coli O157:H7 when the sample tested negative by the Shiga toxin EIA was 98.4% (the negative predictive value of the assay). The probability that the sample contained E. coli O157:H7 when the sample tested positive on the Shiga toxin EIA was 1.5% (the positive predictive value of the assay). The agreement between the 2 tests was poor ( ϭ Ϫ0.002).
The Shiga toxin EIA was designed to detect Shiga toxins regardless of the bacterial species that produce them. Because Shiga toxins are responsible for much of the tissue damage sustained by people infected with Shiga toxin-producing bacteria, the test can be valuable, especially because E. coli O157:H7 is only 1 of many Shiga toxin-producing bacteria. In 1 study, 1 25% of hamburger samples were contaminated with Shiga toxin-producing bacteria, but none of the bacteria were E. coli O157:H7. In the present study, more samples were identified by EIA as containing Shiga toxins than actually contained E. coli O157:H7 as determined by selective bacterial culture. However, the higher number of non-E. coli O157:H7 Shiga toxin-positive samples found in this and other studies might be due to crossreactions with organisms such as Pseudomonas aeruginosa. 2, 13 Of the 36 culture-positive samples, only 2 samples were positive by the Shiga toxin EIA. This result is in stark contrast to the sensitivity and specificity of the assay as determined by use on human fecal samples. According to the product literature, a the sensitivity of EIA for clinical human fecal samples in broth is between 85.1% and 100%, and the specificity is between 95.2% and 99.1%.
The 34 Shiga toxin EIA false-negative samples might be explained by the difference between diarrheal and nondiarrheal feces. The greater amount of particulate matter in bovine feces might diminish the probability of the antigenantibody complex forming. Samples of bovine feces may need to be diluted further before testing with the Shiga toxin EIA. Because E. coli O157:H7 has not been found to colonize bovine tissues, the production of the toxins may have been insufficient (Ͻ7-15 pg/sample well) for the assay to detect. The failure of the assay to detect E. coli O157:H7 could have been because the organism was producing the Shiga toxin variant Stx2e, which the assay does not detect.
Selective bacterial culture is used to identify E. coli O157: H7 in a sample, whereas the EIA is used to identify Shiga toxin in the sample. Because E. coli O157:H7 produces Shiga toxins, the EIA was investigated as a possible screening test for fecal samples collected from clinically healthy animals at livestock establishments to reduce the cost of culturing every sample for E. coli O157:H7. However, the Shiga toxin EIA would not be a practical presumptive test for the presence of E. coli O157:H7 in bovine fecal samples because of its low sensitivity (5.5%) and low positive predictive value for E. coli O157:H7 (1.5%) when compared with selective culture. However, the EIA might be a valuable test for detecting Shiga toxin-producing non-O157:H7 organisms. A more sensitive test than the Shiga toxin EIA should be used when there is an important penalty for false negatives, particularly when the prevalence and the infective dose (Ͻ50 colony-forming units) of the organism is low. 17 Because consumption of contaminated beef may lead to death, the public health penalty for failing to detect E. coli O157:H7 is high.
